Christopher Busapavanij, PA
Medical · Brooklyn, NYNPI 1952589814
Payments from drug & device makers
Across 280 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Pfizer$781
- Incyte Corporation$522
- AbbVie$510
- Sun Pharmaceutical Industries Inc.$397
- Novartis$394
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,73794%
- Education$3856%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 56 | $1,301 |
| Pfizer | 46 | $781 |
| Incyte Corporation | 23 | $522 |
| AbbVie | 22 | $510 |
| Sun Pharmaceutical Industries Inc. | 12 | $397 |
| Novartis | 17 | $394 |
| Lilly USA, LLC | 22 | $335 |
| Sanofi | 9 | $273 |
| E.r. Squibb & Sons, L.L.C. | 10 | $211 |
| Arcutis Biotherapeutics, Inc. | 10 | $206 |
| Regeneron Healthcare Solutions, Inc. | 7 | $178 |
| Amgen | 7 | $173 |
| Mayne Pharma Commercial LLC | 10 | $155 |
| Organon | 6 | $126 |
| UCB, Inc. | 5 | $118 |
| LEO Pharma Inc. | 3 | $71 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $63 |
| Dermavant Sciences, Inc. | 2 | $61 |
| Galderma Laboratories, L.p. | 3 | $61 |
| Cipher Pharmaceuticals US LLC | 1 | $52 |
| Verrica Pharmaceuticals Inc. | 2 | $45 |
| Mylan Institutional Inc. | 1 | $23 |
| EPI Health, LLC | 1 | $23 |
| LNHC, Inc | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
How this compares
$6,123 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Halobetasol Propionate | 37 | $2,066 |
| Ketoconazole | 70 | $1,284 |
| Clobetasol Propionate | 18 | $1,130 |
| Mometasone Furoate | 28 | $566 |
| Triamcinolone Acetonide | 53 | $353 |
| Ammonium Lactate | 14 | $319 |
| Levocetirizine Dihydrochloride | 13 | $117 |
Paid to pharmacies, not to this prescriber.
Other medical in Brooklyn
- Carl ClarkeBrooklyn$116K
- Catherine SekanskyBrooklyn$28K
- Phillip ScottiBrooklyn$22K
- Anna GorelikBrooklyn$15K
- Vita OklanderBrooklyn$13K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Maureen ThyneNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.